- Home
- BMRN vs BXP Comparison
BMRN vs BXP Comparison
Compare BMRN & BXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- BXP
- Stock Information
- Founded
- BMRN 1996
- BXP 1970
- Country
- BMRN United States
- BXP United States
- Employees
- BMRN N/A
- BXP N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- BXP Real Estate Investment Trusts
- Sector
- BMRN Health Care
- BXP Real Estate
- Exchange
- BMRN Nasdaq
- BXP Nasdaq
- Market Cap
- BMRN 10.0B
- BXP 11.4B
- IPO Year
- BMRN 1999
- BXP 1997
- Fundamental
- Price
- BMRN $51.52
- BXP $72.33
- Analyst Decision
- BMRN Buy
- BXP Buy
- Analyst Count
- BMRN 19
- BXP 17
- Target Price
- BMRN $90.26
- BXP $77.71
- AVG Volume (30 Days)
- BMRN 2.8M
- BXP 1.8M
- Earning Date
- BMRN 10-27-2025
- BXP 10-28-2025
- Dividend Yield
- BMRN N/A
- BXP 3.99%
- EPS Growth
- BMRN 59.53
- BXP N/A
- EPS
- BMRN 2.68
- BXP N/A
- Revenue
- BMRN $3,094,001,000.00
- BXP $3,275,851,000.00
- Revenue This Year
- BMRN $13.32
- BXP $2.59
- Revenue Next Year
- BMRN $7.51
- BXP $2.31
- P/E Ratio
- BMRN $19.20
- BXP N/A
- Revenue Growth
- BMRN 12.39
- BXP N/A
- 52 Week Low
- BMRN $50.76
- BXP $54.22
- 52 Week High
- BMRN $73.51
- BXP $84.75
- Technical
- Relative Strength Index (RSI)
- BMRN 40.53
- BXP 52.07
- Support Level
- BMRN $51.80
- BXP $68.01
- Resistance Level
- BMRN $53.49
- BXP $74.77
- Average True Range (ATR)
- BMRN 1.84
- BXP 1.77
- MACD
- BMRN -0.08
- BXP -0.10
- Stochastic Oscillator
- BMRN 12.58
- BXP 63.02
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About BXP Boston Properties Inc.
BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.